Dear Members,

The question is… What is the New Spotlight Stock we are Announcing This Weekend?!

This weekend we are going to be announcing our latest covered company, and it’s a very good one. I will be sharing the symbol with you this weekend, but I wanted to give you a heads up.

The Company featured had pharmaceutical products already on the market, including a number of ones you will recognize from your shopping at your favorite drug store or drug aisle in your grocery store. You may even have some of their products at home.

On top of that, the Company has worked with many major pharmaceutical companies worldwide, creating products and improving products for them.

The Company is diligently working to get a drug formulation designated an an “orphan drug” by both the FDA and the European equivalent of the FDA, the European Medicines Agency (“EMA”). That process has been underway, starting two years ago, and continues to this day.

Once they achieve this, valuation for the Company is likely to dramatically increase beyond it’s less than $4 million market cap.

When I introduce the Company to you on Saturday morning, please be ready to do your due diligence.

Here are a couple of links about the importance of “orphan drug designation.”

FDA: Designating an Orphan Product: Drugs and Biologics

The New York Times: Making ‘Every Patient Counts’ a Business Imperative (This story covers a different drug treating a different condition, but it also explains why orphan drug designation is so important for patients.)

Orphan Drug Designation – The United States and Europe

Wikipedia.com: The Orphan Drug Act in the US and Regulation(EC) No 141/2000 in the EU. 

Remember – these Congressional and EU Legislative regulations are there to benefit the patient of a very rare or “orphan disease” by making it financially beneficial to the drug company’s making these drugs. On Saturday I will further explain this and introduce you to the very important disease that is truly devastating that this Company is working to bring a huge step forward in treatment.

On Friday I am going to share some companies that achieved the orphan drug designation for their formulations, and what it meant for the patients and those companies.

More on this on Friday.  I will share all about this Company and its journey to gain the designation for one of its drugs on Saturday.

Have a great day trading Friday. For all of you in the zone affected by the blizzard forecast, stay safe and warm!

John Pentony
Publisher, StockGuru.com